Harrow (NASDAQ:HROW) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Harrow (NASDAQ:HROW) in a report issued on Thursday,Benzinga reports. They currently have a $70.00 price target on the stock.

Several other brokerages have also issued reports on HROW. BTIG Research reissued a “buy” rating and issued a $63.00 target price on shares of Harrow in a research report on Wednesday. William Blair restated an “outperform” rating on shares of Harrow in a research report on Tuesday, March 3rd. Nomura cut Harrow to a “neutral” rating in a research note on Wednesday. Zacks Research downgraded Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Harrow has an average rating of “Moderate Buy” and a consensus target price of $71.14.

Harrow Stock Performance

Shares of HROW opened at $34.41 on Thursday. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.06. Harrow has a one year low of $20.85 and a one year high of $54.85. The company has a 50-day simple moving average of $44.80 and a two-hundred day simple moving average of $43.49. The firm has a market capitalization of $1.28 billion, a PE ratio of -202.40 and a beta of 0.05.

Hedge Funds Weigh In On Harrow

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Harrow in the 4th quarter worth $26,000. SBI Securities Co. Ltd. increased its holdings in Harrow by 393.5% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after buying an additional 846 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Harrow in the 2nd quarter worth about $48,000. State of Alaska Department of Revenue purchased a new stake in shares of Harrow during the 3rd quarter valued at about $83,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Harrow by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after acquiring an additional 369 shares during the period. 72.76% of the stock is owned by institutional investors.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.